ARTICLE | Finance
Amicable for Amicus
Amicus, GSK revise Fabry's deal, biotech gets U.S. rights to migalastat
July 23, 2012 7:00 AM UTC
Orphan disease play Amicus Therapeutics Inc. (NASDAQ:FOLD) gave up potential milestone payments from partner GlaxoSmithKline plc last week and assumed more development costs in exchange for U.S. commercial rights in their Fabry's disease deal.
The biotech ceded $166.5 million in milestones and assumed 40% of R&D expenses, up from 25%...